MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib

ABSTRACT: Angiogenesis inhibitors, such as sunitinib, represent a promising strategy to improve glioblastoma (GBM) tumor response. In this study, we used the O6-methylguanine methyltransferase (MGMT)-negative GBM cell line U87MG stably transfected with MGMT (U87/MGMT) to assess whether MGMT expression affects the response to sunitinib. We showed that the addition of sunitinib to standard therapy (temozolomide [TMZ] and radiation therapy [RT]) significantly improved the response of MGMT positive but not of MGMT-negative cells. Gene expression profiling revealed alterations in the angiogenic profile, as well as differential expression of several receptor tyrosine kinases targeted by sunitinib. MGMT-positive cells displayed higher levels of vascular endothelial growth factor receptor 1 (VEGFR-1) compar

ORGANISM(S): Homo sapiens

SUBMITTER: Chahal M 

PROVIDER: S-ECPF-GEOD-40776 | biostudies-other | 2010 Aug

REPOSITORIES: biostudies-other